Trickey A, Sabin CA, Burkholder G, Crane H, d'Arminio Monforte A, Egger M, Gill MJ, Grabar S, Guest JL, Jarrin I, et al: Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: A collaborative analysis of cohort studies. Lancet HIV. 10:e295–e307. 2023.PubMed/NCBI View Article : Google Scholar

Marino A, Zafarana G, Ceccarelli M, Cosentino F, Moscatt V, Bruno G, Bruno R, Benanti F, Cacopardo B and Celesia BM: Immunological and clinical impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience. Diagnostics (Basel). 11(2336)2021.PubMed/NCBI View Article : Google Scholar

D'Andrea F, Venanzi Rullo E, Marino A, Moscatt V, Celesia BM, Cacopardo B, Condorelli F, La Rocca G, Di Rosa M, Pellicanò GF, et al: Hepatitis B virus infection and hepatocellular carcinoma in PLWH: Epidemiology, pathogenesis and treatment. World Cancer Res J. 7(e1537)2020.

Peters E and Iwuji AC: Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review. Antivir Ther. 28(13596535231159030)2023.PubMed/NCBI View Article : Google Scholar

Celesia BM, Marino A, del Vecchio RF, Bruno R, Palermo F, Gussio M, Nunnari G and Cacopardo B: Is it Safe and Cost Saving to Defer the CD4+ cell count monitoring in stable patients on art with more than 350 or 500 cells/µl? Mediterr J Hematol Infect Dis. 11(e2019063)2019.PubMed/NCBI View Article : Google Scholar

Celesia BM, Marino A, Borracino S, Arcadipane AF, Pantò G, Gussio M, Coniglio S, Pennisi A, Cacopardo B and Panarello G: Successful extracorporeal membrane oxygenation treatment in an acquired immune deficiency syndrome (AIDS) patient with acute respiratory distress syndrome (ARDS) Complicating Pneumocystis jirovecii Pneumonia: A Challenging Case. Am J Case Rep. 21(e919570)2020.PubMed/NCBI View Article : Google Scholar

Micali C, Russotto Y, Facciolà A, Marino A, Celesia BM, Pistarà E, Caci G, Nunnari G, Pellicanò GF and Venanzi Rullo E: Pulmonary kaposi sarcoma without respiratory symptoms and skin lesions in an HIV-Naïve Patient: A case report and literature review. Infect Dis Rep. 14:228–242. 2022.PubMed/NCBI View Article : Google Scholar

Ambrosioni J, Levi L, Alagaratnam J, Van Bremen K, Mastrangelo A, Waalewijn H, Molina JM, Guaraldi G, Winston A, Boesecke C, et al: Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 24:1126–1136. 2023.PubMed/NCBI View Article : Google Scholar

Marino A, Cosentino F, Ceccarelli M, Moscatt V, Pampaloni A, Scuderi D, D'Andrea F, Rullo EV, Nunnari G, Benanti F, et al: Entecavir resistance in a patient with treatment-naïve HBV: A case report. Mol Clin Oncol. 14(113)2021.PubMed/NCBI View Article : Google Scholar

Marino A, Pavone G, Martorana F, Fisicaro V, Motta L, Spampinato S, Celesia BM, Cacopardo B, Vigneri P and Nunnari G: Navigating the Nexus: HIV and Breast Cancer-A Critical Review. Int J Mol Sci. 25(3222)2024.PubMed/NCBI View Article : Google Scholar

Ron R, Martínez-Sanz J, Herrera S, Ramos-Ruperto L, Díez A, Sainz T, Álvarez-Díaz N, Correa-Pérez A, Muriel A, López-Alcalde J, et al: CD4/CD8 ratio and CD8+ T-cell count as prognostic markers for non-AIDS mortality in people living with HIV. A systematic review and meta-analysis. Front Immunol. 15(1343124)2024.PubMed/NCBI View Article : Google Scholar

Serrano-Villar S, Wu K, Hunt PW, Lok JJ, Ron R, Sainz T, Moreno S, Deeks SG and Bosch RJ: Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. EBioMedicine. 80(104072)2022.PubMed/NCBI View Article : Google Scholar

World Health Organization (WHO): Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. WHO, Geneva, 2021.

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, et al: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 367:399–410. 2012.PubMed/NCBI View Article : Google Scholar

Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, Mugo NR, Wald A, Corey L, Donnell D, et al: Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 3(77ra29)2011.PubMed/NCBI View Article : Google Scholar

Acosta RK, Willkom M, Andreatta K, Liu H, Martin R, Parvangada A, Martin H, Collins S and White KL: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. J Acquir Immune Defic Syndr. 85:363–371. 2020.PubMed/NCBI View Article : Google Scholar

Chang HM, Chou PY, Chou CH and Tsai HC: Outcomes After Switching to BIC/FTC/TAF in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: A real-world cohort study. Infect Drug Resist. 14:4877–4886. 2021.PubMed/NCBI View Article : Google Scholar

Chen LY, Sun HY, Chuang YC, Huang YS, Liu WD, Lin KY, Chang HY, Luo YZ, Wu PY, Su YC, et al: Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide. J Microbiol Immunol Infect. 56:575–585. 2023.PubMed/NCBI View Article : Google Scholar

Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, et al: Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 5:e347–e356. 2018.PubMed/NCBI View Article : Google Scholar

De Socio GV, Tordi S, Altobelli D, Gidari A, Zoffoli A and Francisci D: Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV. J Clin Med. 12(7759)2023.PubMed/NCBI View Article : Google Scholar

Hagins D, Kumar P, Saag M, Wurapa AK, Brar I, Berger D, Osiyemi O, Hileman CO, Ramgopal MN, McDonald C, et al: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. J Acquir Immune Defic Syndr. 88:86–95. 2021.PubMed/NCBI View Article : Google Scholar

Kityo C, Hagins D, Koenig E, Avihingsanon A, Chetchotisakd P, Supparatpinyo K, Gankina N, Pokrovsky V, Voronin E, Stephens JL, et al: Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. J Acquir Immune Defic Syndr. 82:321–328. 2019.PubMed/NCBI View Article : Google Scholar

Knobel H, Cañas-Ruano E, Guelar A, Knobel P, Villar-García J, González-Mena A, Canepa C, Arrieta-Aldea I, Marcos A, Abalat-Torrres A and Güerri-Fernández R: Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study. HIV Res Clin Pract. 24(2239564)2023.PubMed/NCBI

Lake JE, Hyatt AN, Feng H, Debroy P, Kettelhut A, Miao H, Peng L, Bhasin S, Bell S, Rianon N, et al: A randomized clinical trial of transgender women switching to B/F/TAF: The (mo)BETTA Trial. Open Forum Infect Dis. 10(ofad178)2023.PubMed/NCBI View Article : Google Scholar

Lazzaro A, Cacciola EG, Borrazzo C, Innocenti GP, Cavallari EN, Mezzaroma I, Falciano M, Fimiani C, Mastroianni CM, Ceccarelli G and d'Ettorre G: Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort. Diagnostics (Basel). 12(76)2021.PubMed/NCBI View Article : Google Scholar

Lazzaro A, Bianchini D, Gentilini Cacciola E, Mezzaroma I, Falciano M, Andreoni C, Fimiani C, Santinelli L, Maddaloni L, Bugani G, et al: Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort. Viruses. 15(1222)2023.PubMed/NCBI View Article : Google Scholar

Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML, Blair C, Chuck SK, et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial. Infect Dis Ther. 10:775–788. 2021.PubMed/NCBI View Article : Google Scholar

Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, et al: Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 5:e357–e365. 2018.PubMed/NCBI View Article : Google Scholar

Tsai MS, Sun HY, Chen CP, Lee CH, Lee CY, Liu CE, Tang HJ, Hung TC, Li CW, Lee YT, et al: Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation. Int J Infect Dis. 126:39–47. 2023.PubMed/NCBI View Article : Google Scholar

Rolle CP, Nguyen V, Patel K, Cruz D, DeJesus E and Hinestrosa F: Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV. Medicine (Baltimore). 100(e27330)2021.PubMed/NCBI View Article : Google Scholar

Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, Rieger A, Liu H, Acosta R, Collins SE, et al: Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin Infect Dis. 73:e485–e493. 2021.PubMed/NCBI View Article : Google Scholar

Klatzmann D, Barré-Sinoussi F, Nugeyre MT, Danquet C, Vilmer E, Griscelli C, Brun-Veziret F, Rouzioux C, Gluckman JC, Chermann JC, et al: Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science. 225:59–63. 1984.PubMed/NCBI View Article : Google Scholar

Doitsh G and Greene WC: Dissecting How CD4 T Cells Are Lost During HIV Infection. Cell Host Microbe. 19:280–291. 2016.PubMed/NCBI View Article : Google Scholar

Bishop JD, DeShields S, Cunningham T and Troy SB: CD4 count recovery after initiation of antiretroviral therapy in patients infected with human immunodeficiency virus. Am J Med Sci. 352:239–244. 2016.PubMed/NCBI View Article : Google Scholar

Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:123–126. 1995.PubMed/NCBI View Article : Google Scholar

Roederer M, Dubs JG, Anderson MT, Raju PA and Herzenberg LA and Herzenberg LA: CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest. 95:2061–2066. 1995.PubMed/NCBI View Article : Google Scholar

Favre D, Stoddart CA, Emu B, Hoh R, Martin JN, Hecht FM, Deeks SG and McCune JM: HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. Blood. 117:2189–2199. 2011.PubMed/NCBI View Article : Google Scholar

Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, Sontag G, Sewell AK and Phillips RE: Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA. 97:3382–3387. 2000.PubMed/NCBI View Article : Google Scholar

Badejo OA, Chang CC, So-Armah KA, Tracy RP, Baker JV, Rimland D, Butt AA, Gordon AJ, Rinaldo CR Jr, Kraemer K, et al: CD8+ T-Cells Count in Acute Myocardial Infarction in HIV disease in a predominantly male cohort. Biomed Res Int. 2015(246870)2015.PubMed/NCBI View Article : Google Scholar

Schneider S, Spinner CD, Cassese S, Promny D, Hapfelmeier A, Byrne RA, Baumann M, Jäger H, Steinlechner E, Laugwitz KL and Kastrati A: Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. AIDS. 30:1413–1421. 2016.PubMed/NCBI View Article : Google Scholar

Borges ÁH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugyenyi P, Domingo P, Hoffmann C, Read TR, et al: Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV Infection. Clin Infect Dis. 63:1668–1676. 2016.PubMed/NCBI View Article : Google Scholar

Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d'Arminio A, Cavassini M, Smith C, et al: Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS. 29:221–229. 2015.PubMed/NCBI View Article : Google Scholar

Castilho JL, Shepherd BE, Koethe J, Turner M, Bebawy S, Logan J, Rogers WB, Raffanti S and Sterling TR: CD4+/CD8+ ratio, age, and risk of serious non-communicable diseases in HIV-infected adults on antiretroviral therapy. AIDS. 30:899–908. 2016.PubMed/NCBI View Article : Google Scholar

Dock JN and Effros RB: Role of CD8 T cell replicative senescence in human aging and in HIV-mediated Immunosenescence. Aging Dis. 2:382–397. 2011.PubMed/NCBI

Avelino-Silva VI, Miyaji KT, Hunt PW, Huang Y, Simoes M, Lima SB, Freire MS, Caiaffa-Filho HH, Hong MA, Costa DA, et al: CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. PLoS Negl Trop Dis. 10(e0005219)2016.PubMed/NCBI View Article : Google Scholar

Collin A, Le Marec F, Vandenhende MA, Lazaro E, Duffau P, Cazanave C, Gérard Y, Dabis F, Bruyand M and Bonnet F: ANRS CO3 Aquitaine Cohort Study Group. Incidence and risk factors for severe bacterial infections in people living with HIV. ANRS CO3 Aquitaine Cohort, 2000-2012. PLoS One. 11(e0152970)2016.PubMed/NCBI View Article : Google Scholar

Vrinceanu D, Dumitru M, Patrascu OM, Costache A, Papacocea T and Cergan R: Current diagnosis and treatment of rhinosinusal aspergilloma (Review). Exp Ther Med. 22(1264)2021.PubMed/NCBI View Article : Google Scholar

Saydam FN, Erdem H, Ankarali H, El-Arab Ramadan ME, El-Sayed NM, Civljak R, Pshenichnaya N, Moroti RV, Mahmuodabad FM, Maduka AV, et al: Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia. Travel Med Infect Dis. 44(102174)2021.PubMed/NCBI View Article : Google Scholar

Sigel K, Wisnivesky J, Crothers K, Gordon K, Brown ST, Rimland D, Rodriguez-Barradas MC, Gibert C, Goetz MB, Bedimo R, et al: Immunological and infectious risk factors for lung cancer in US veterans with HIV: A longitudinal cohort study. Lancet HIV. 4:e67–e73. 2017.PubMed/NCBI View Article : Google Scholar

Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, Fu Y, Dart A, Orenstein JM, Bobryshev YV, et al: Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 4(e365)2006.PubMed/NCBI View Article : Google Scholar

Lu L, Yang Y, Yang Z, Wu Y, Liu X, Li X, Chen L, Han Y, Song X, Kong Z, et al: Altered plasma metabolites and inflammatory networks in HIV-1 infected patients with different immunological responses after long-term antiretroviral therapy. Front Immunol. 14(1254155)2023.PubMed/NCBI View Article : Google Scholar

Papantoniou E, Arvanitakis K, Markakis K, Papadakos SP, Tsachouridou O, Popovic DS, Germanidis G, Koufakis T and Kotsa K: Pathophysiology and clinical management of dyslipidemia in people living with HIV: Sailing through Rough Seas. Life (Basel). 14(449)2024.PubMed/NCBI View Article : Google Scholar

Stanley TL and Grinspoon SK: Body composition and metabolic changes in HIV-Infected Patients. J Infect Dis. 205 (Suppl 3):S383–S390. 2012.PubMed/NCBI View Article : Google Scholar

Avihingsanon A, Chetchotisakd P, Kiertiburanakul S, Ratanasuwan W, Siripassorn K, Supparatpinyo K, Martin H, Wang H, Wong T and Wang HY: Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials. HIV Med. 24:290–300. 2023.PubMed/NCBI View Article : Google Scholar

Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML, Blair C, Chuck SK, et al: Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age. HIV Med. 24:27–36. 2023.PubMed/NCBI View Article : Google Scholar

Squillace N, Ricci E, Maggi P, Taramasso L, Menzaghi B, De Socio GV, Piconi S, Maurizio Celesia B, Orofino G, Sarchi E, et al: Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir. PLoS One. 18(e0289132)2023.PubMed/NCBI View Article : Google Scholar

Perrone RD, Madias NE and Levey AS: Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 38:1933–1953. 1992.PubMed/NCBI

Kashani K, Rosner MH and Ostermann M: Creatinine: From physiology to clinical application. Eur J Intern Med. 72:9–14. 2020.PubMed/NCBI View Article : Google Scholar

Ando M and Yanagisawa N: Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients. World J Nephrol. 4:388–395. 2015.PubMed/NCBI View Article : Google Scholar

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, et al: Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D study. J Infect Dis. 207:1359–1369. 2013.PubMed/NCBI View Article : Google Scholar

Pottel H, Vrydags N, Mahieu B, Vandewynckele E, Croes K and Martens F: Establishing age/sex related serum creatinine reference intervals from hospital laboratory data based on different statistical methods. Clin Chim Acta. 396:49–55. 2008.PubMed/NCBI View Article : Google Scholar

Yamada J, Tomiyama H, Yambe M, Koji Y, Motobe K, Shiina K, Yamamoto Y and Yamashina A: Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis. 189:198–205. 2006.PubMed/NCBI View Article : Google Scholar

Nixon DE and Landay AL: Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 5:498–503. 2010.PubMed/NCBI View Article : Google Scholar

Siest G, Schiele F, Galteau MM, Panek E, Steinmetz J, Fagnani F and Gueguen R: Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem. 21:1077–1087. 1975.PubMed/NCBI

Sookoian S and Pirola CJ: Liver enzymes, metabolomics and genome-wide association studies: From systems biology to the personalized medicine. World J Gastroenterol. 21:711–725. 2015.PubMed/NCBI View Article : Google Scholar